Cutler Group LP Veracyte, Inc. Transaction History

Cutler Group LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 19, 2021	SELL	$32.94 - $56.62 $13,176 - $22,648	-400 Closed	0 $0
Q1 2021 Apr 26, 2021	BUY	$44.47 - $81.38 $17,788 - $32,552	400 New	400 $21,000
Q2 2018 Aug 10, 2018	SELL	$5.39 - $9.66 $17,846 - $31,984	-3,311 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$5.44 - $6.97 $29,920 - $38,335	-5,500 Reduced 62.42%	3,311 $18,000
Q4 2017 Jan 17, 2018	SELL	$6.05 - $9.37 $189,262 - $293,121	-31,283 Reduced 78.02%	8,811 $57,000
Q3 2017 Oct 17, 2017	BUY	$7.81 - $8.77 $313,134 - $351,624	40,094	40,094 $351,000

307

81.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.97B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.